Cargando…
Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts
BACKGROUND: Lipoarabinomannan (LAM) is a major antigen of Mycobacterium tuberculosis (MTB). In this report, we evaluated the ability of a novel immunoassay to measure concentrations of LAM in sputum as a biomarker of bacterial load prior to and during treatment in pulmonary tuberculosis (TB) patient...
Autores principales: | Kawasaki, Masanori, Echiverri, Carmenchu, Raymond, Lawrence, Cadena, Elizabeth, Reside, Evelyn, Gler, Maria Tarcela, Oda, Tetsuya, Ito, Ryuta, Higashiyama, Ryo, Katsuragi, Kiyonori, Liu, Yongge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461223/ https://www.ncbi.nlm.nih.gov/pubmed/30978194 http://dx.doi.org/10.1371/journal.pmed.1002780 |
Ejemplares similares
-
Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts
por: Jones, Aksana, et al.
Publicado: (2022) -
Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients
por: Broger, Tobias, et al.
Publicado: (2019) -
A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose–Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis
por: Sigal, George B., et al.
Publicado: (2018) -
Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes
por: Podewils, Laura Jean, et al.
Publicado: (2013) -
Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?
por: Sabur, Natasha F., et al.
Publicado: (2017)